latrepirdine has been researched along with furosemide in 1 studies
Studies (latrepirdine) | Trials (latrepirdine) | Recent Studies (post-2010) (latrepirdine) | Studies (furosemide) | Trials (furosemide) | Recent Studies (post-2010) (furosemide) |
---|---|---|---|---|---|
126 | 7 | 59 | 13,631 | 1,358 | 2,486 |
Protein | Taxonomy | latrepirdine (IC50) | furosemide (IC50) |
---|---|---|---|
Corticosteroid 11-beta-dehydrogenase isozyme 1 | Homo sapiens (human) | 3.76 | |
Corticosteroid 11-beta-dehydrogenase isozyme 1 | Mus musculus (house mouse) | 3.76 | |
Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 3.2 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
1 other study(ies) available for latrepirdine and furosemide
Article | Year |
---|---|
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |